Featured Research

from universities, journals, and other organizations

Botulinum toxin provides clinically meaningful benefit for idiopathic OAB patients

Date:
April 19, 2010
Source:
European Association of Urology
Summary:
Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. Botox may provide a minimally invasive effective treatment.

Treatment options for idiopathic OAB (IOAB) patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple (GB) and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.

Related Articles


The results were presented recently at the Anniversary EAU Congress in Barcelona.

Chris Chapple: "IOAB patients with urinary urgency incontinence (UUI) whose symptoms are not adequately managed with anticholinergic therapy were recruited. Patients were randomised to receive BOTOX® 50U, 100U, 150U, 200U or 300U or placebo. This was administered as intradetrusor injections."

Patients were followed for 36 weeks post-treatment with assessments including 7-day bladder diary, post void residual urine volume (PVR), health-related quality of life (HRQOL) questionnaires and urodynamics.

Chris Chapple: "We were happy to see durable and clinically meaningful efficacy for all BOTOX® dose groups of 100U and above with significant reductions from baseline compared to placebo in patient symptoms, including being incontinence-free."

Dose response was identified in efficacy parameters; however a UUI analysis demonstrated minimal additional efficacy at BOTOX® doses above 150U and several HRQOL measures showed minimal incremental benefit above 100U.

Safety findings primarily related to local pharmacological effects on the bladder resulting in dose dependant increases in PVR. Adverse events significantly higher in BOTOX® dose groups compared to placebo were UTI and urinary retention; the proportion of patients using clean intermittent catheterisation (CIC) increased with dose. Dose response was identified in safety parameters, particularly in the proportion of patients having a PVR ≥ 200mL, a threshold associated with considerable increases in the use of CIC and adverse events such as urinary tract infection and urinary retention.

"This double-blind, placebo-controlled study demonstrated that BOTOX® provides a clinically meaningful benefit. The benefit / risk ratio has been evaluated over a broad range of BOTOX® doses in the idiopathic OAB population and doses of 100U -- 150U provide the appropriate benefit / risk balance. The clinically meaningful benefit is balanced with dose-dependant PVR elevation" Prof. Chapple concluded.


Story Source:

The above story is based on materials provided by European Association of Urology. Note: Materials may be edited for content and length.


Cite This Page:

European Association of Urology. "Botulinum toxin provides clinically meaningful benefit for idiopathic OAB patients." ScienceDaily. ScienceDaily, 19 April 2010. <www.sciencedaily.com/releases/2010/04/100419113703.htm>.
European Association of Urology. (2010, April 19). Botulinum toxin provides clinically meaningful benefit for idiopathic OAB patients. ScienceDaily. Retrieved December 21, 2014 from www.sciencedaily.com/releases/2010/04/100419113703.htm
European Association of Urology. "Botulinum toxin provides clinically meaningful benefit for idiopathic OAB patients." ScienceDaily. www.sciencedaily.com/releases/2010/04/100419113703.htm (accessed December 21, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, December 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) — It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) — More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) — In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
The Best Protein-Filled Foods to Energize You for the New Year

The Best Protein-Filled Foods to Energize You for the New Year

Buzz60 (Dec. 19, 2014) — The new year is coming and nothing will energize you more for 2015 than protein-filled foods. Fitness and nutrition expert John Basedow (@JohnBasedow) gives his favorite high protein foods that will help you build muscle, lose fat and have endless energy. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins